Abstract
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma that may become refractory to available standard therapies, resulting in the need for the development of novel therapeutic targets. Increased metabolic activity of DLBCL tumor cells associated with high expression of glycolysis related proteins, such as glucose transporters and hexokinases, have already been described and indicates a pivotal role for glucose and glycogen metabolism in the malignant progression of the disease. Moreover, several enzymes involved in glycolysis and glycogen metabolism, including hexokinases and glycogen synthase kinase-3, are key molecules in mediating cell survival signaling, indicating that glucose/glycogen metabolism is tightly linked to the cell survival and can potentially be targeted for therapeutic purposes in DLBCL. In this review, we provide a summary of glycogen and glucose metabolism and discuss their significance in the metabolic reprograming that leads to cell survival and proliferation in DLBCL.
Original language | English (US) |
---|---|
Pages (from-to) | 1028-1036 |
Number of pages | 9 |
Journal | Leukemia and Lymphoma |
Volume | 61 |
Issue number | 5 |
DOIs | |
State | Published - Apr 15 2020 |
Keywords
- DLBCL
- Glucose metabolism
- glycogen metabolism
- lymphoma
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research